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Abstract Dronedarone has been associated with a
reduced number of first hospitalisation due to acute cor-
onary syndromes. Whether this is only due to the reduc-
tion in ventricular heart rate and blood pressure or
whether other effects of dronedarone may be involved is
currently elusive. This study was designed to investigate
the role of dronedarone in arterial thrombus formation.
C57Bl/6 mice were treated with dronedarone and arterial
thrombosis was investigated using a mouse photochemical
injury model. Dronedarone inhibited carotid artery
thrombus formation in vivo (P \ 0.05). Thrombin- and
collagen-induced platelet aggregation was impaired in
dronedarone-treated mice (P \ 0.05), and expression of
plasminogen activator inhibitor-1 (PAI1), an inhibitor of
the fibrinolytic system, was reduced in the arterial wall
(P \ 0.05). In contrast, the level of tissue factor (TF), the
main trigger of the coagulation cascade, and that of its
physiological inhibitor, TF pathway inhibitor, did not
differ. Similarly, coagulation times as measured by pro-
thrombin time and activated partial thromboplastin time
were comparable between the two groups. Dronedarone
inhibits thrombus formation in vivo through inhibition of
platelet aggregation and PAI1 expression. This effect
occurs within the range of dronedarone concentrations
measured in patients, and may represent a beneficial
pleiotropic effect of this drug.
Keywords Dronedarone  Arterial thrombosis  Animal
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Introduction
Atrial fibrillation (AF) is the most common sustained
arrhythmia in the Western world and represents a major
health burden [10, 12]. Management of patients with AF
focuses either on rhythm-control or rate-control strategies
as well as the on prevention of thromboembolic events.
The most commonly used anti-arrhythmic drug is amio-
darone; nevertheless, its use is restricted due to its wide
range of adverse side effects such as thyroid and pulmon-
ary toxicity. Dronedarone, a benzofuran derivative with
electrophysiological properties similar to amiodarone, was
therefore designed to function as an alternative to amio-
darone [25]. In several clinical trials, dronedarone delayed
the time to first recurrence of AF and also decreased the
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number of recurrences [14, 19, 24]. Indeed, in the drone-
darone trial to asses the prevention of cardiovascular hos-
pitalization or death in patients with AF (ATHENA),
dronedarone treatment was associated with a significant
reduction in first cardiovascular hospitalisations as well as
death from cardiovascular causes; interestingly, there were
also fewer first hospitalisations for acute coronary syn-
dromes (ACS; P = 0.03 for the dronedarone-treated group
versus control) [14]. Whether this is only due to the anti-
ischemic effect of lower ventricular heart rate or a result of
an additional mechanism such as direct inhibition of
thrombus formation currently remains unknown.
This study was therefore designed to investigate whether
dronedarone, in addition to its electrophysiological prop-
erties, inhibits arterial thrombus formation.
Materials and methods
Dronedarone plasma and tissue concentrations
Concentrations of dronedarone in mouse plasma and tho-
racic aorta were measured by high performance liquid
chromatography [HPLC; LiChrospher60, 5C18; 250
9 i.d. 4 mm; mobile phase: methanol:water:25 % NH3
(89.47:8.77:1.76 w/w); flow rate: 1 mL/min]. Aorta
(25 mg) was homogenized in 0.5 mL methanol at 4 C
using a Potter S glass homogenizer (Braun, Melsungen,
Germany). After centrifugation at 3,000g, the pellet was
washed twice with 0.25 mL methanol. The organic extracts
were pooled and evaporated to dryness (Speed Vac, Savant
Instruments Inc., Farmingdale, NY, USA). The residue was
dissolved in 75 lL water, and an aliquot of 50 lL was
analyzed. Plasma (200 lL) was mixed with 0.1 mL
0.5 mM KH2PO4 and extracted three times with 0.75 mL
diethylether. The organic extracts were pooled and evap-
orated to dryness as described. The residue was dissolved
in 100 lL of methanol, and an aliquot of 50 lL was used
for HPLC.
Carotid artery thrombosis model
Twelve-week-old C57Bl/6 mice were divided into two
groups: dronedarone (200 mg/kg body weight with a
once daily oral gavage for 14 days) or control (1.4 %
methylcellulose). Twenty-four hours after the last appli-
cation, mice were anesthetized by intraperitoneal injec-
tion of 87 mg/kg sodium pentobarbital (Butler,
Columbus, OH, USA). Rose bengal (Fisher Scientific,
Fair Lawn, NJ, USA) was diluted to 12 mg/mL in
phosphate-buffered saline and then injected into the tail
vein at a concentration of 63 mg/kg. Mice were secured
in a supine position, placed under a dissecting
microscope, and the right common carotid artery was
exposed following a midline cervical incision. A Doppler
flow probe (Model 0.5 VB, Transonic Systems, Ithaca,
NY, USA) was applied and connected to a flowmeter
(Transonic, Model T106). 6 min after rose bengal
injection, a 1.5-mW green light laser (540 nm; Melles
Griot, Carlsbad, CA, USA) was applied to the site of
injury at a distance of 6 cm for 60 min or until throm-
bosis occurred. From the onset of injury, blood flow was
monitored up to 120 min, at which time the experiment
was terminated [4]. Occlusion was defined as flow
B0.1 mL/min for at least 1 min.
Platelet count
Platelets were counted by flow cytometry using whole
blood collected in EDTA tubes (B&D Diagnostics,
Franklin Lakes, NJ, USA).
Reticulated platelet staining
Reticulated platelets are stained by mixing 5 lL of EDTA-
anticoagulated blood with 50 lL Thiazole Orange solution
(0.1 lg/mL in PBS). Samples are incubated 15 min at
room temperature and then fixed by adding 1 % PFA in
PBS, and immediately analyzed on a FacsCanto (BD
Bioscience). Platelets are gated based on their FSC/SSC
characteristics and % positive platelets determined with
BD FacsDiva software.
Glycocalicin index
Plasma glycocalicin is determined by enzyme linked
immunosorbent assay (ELISA). Briefly, flat-bottom
96-well plates (Costar) are coated overnight with an
antibody against the extracellular domain of murine
GPIba (generous gift of B. Nieswandt), overnight at 4 C.
Wells are then washed with PBS-Tween 0.1 % and
blocked with 5 % milk-5 % BSA in PBS for 2 h at 37 C.
After washing, they are incubated with duplicate standard
(pooled mouse plasma) and samples at 1:10 and 1:20
dilution in 1 % milk–1 % BSA at 37 C for 1 h. Wells
are washed and incubated with a second antibody against
GPIba conjugated to HRP for 30 min. After washing,
wells are incubated with TMB substrate reagent (BD
Bioscience) for 5 min, and reaction is stopped by adding
0.5 M sulphuric acid. Optical densities are read at 450 nm
on a Versamax plate reader (Molecular Devices) and
glycocalicin concentrations are calculated by the SoftMax
Pro software based on the standard curve. Glycocalicin
index is calculated by multiplying the plasma glycocalicin
concentration for the platelet count normalized to
250,000/lL.
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Platelet aggregation studies
Platelet aggregation was studied using a Chrono-Log whole
blood impedance aggregometer (Chrono-Log, Havertown,
PA, USA). For studies performed in murine platelets, cit-
rated blood was drawn by puncture from the right ventricle.
Aggregation studies were performed with citrated blood
within 1 h. Platelets were equilibrated under constant
stirring for 1 min prior to addition of human thrombin
(0.5 U/mL; Sigma Aldrich, Frankfurt, Germany), ADP
(20 mU/mL; Chrono-Log), equine collagen type 1 (5 lg/mL;
Chrono-Log), ADP (20 lM; Chrono-Log), or botrocetin
(0.5 mg/mL; Sigma Aldrich). Aggregation was displayed as
a function of time (AGGRO/LINK Software; Chrono-Log).
Results were expressed as maximal aggregation (X), and lag
time (s).
Coagulation times
Prothrombin time (PT) and activated partial thromboplastin
time (aPTT) were assessed by the Start4 analyzer (Diag-
nostica Stago, Paris, France) with according reagents
(Roche Diagnostics, Basel, Switzerland). Plasma from
citrated blood (3.8 % citrate 1/10) was extracted by 10 min
centrifugation (2,100g, 4 C), and stored immediately at
-80 C until analyzed.
Vessel wall mRNA and protein analysis
Total RNA was isolated using RNeasy Mini Kit (Qiagen,
Hilden, Germany). cDNA was generated using Ready-To-
Go You-Prime First-Strand Beads (Amersham Bioscience,
Glattbrugg, Switzerland) and first-strand cDNA primer.
Quantitative real-time polymerase chain reaction was per-
formed using SybrGreen Jump start kit (Sigma Aldrich).
Primers were designed to detect mouse TF, TFPI and PAI1.
Data were normalized for murine L28 and analyzed by the
comparative DCT method.
For protein analysis, aortas of mice were homogenized
in 50 mL of lysis buffer (50 mmol Tris–HCl, 100 mmol
NaCl, 0.1 % Triton X-100, pH 7.4) and left to stand on
ice for 30 min. One hundred microgram samples were
loaded and separated by 10 % SDS-PAGE; proteins were
transferred to a PVDF membrane and probed with an
antibody to PAI1 (1:1,000 dilution). Equal protein loading
was determined by staining for a-tubulin (1:10,000
dilution).
Statistical analysis
Data are indicated as mean ± SEM. For statistical analy-
sis, one-way ANOVA was performed with a post hoc
analysis. A P value\0.05 denoted a significant difference.
Results
Dronedarone inhibits arterial thrombus formation
at a clinically relevant plasma concentration
Mice were treated with either dronedarone (200 mg/kg
body weight once daily) or vehicle, respectively. Drone-
darone plasma concentration was 0.12 ± 0.014 lg/mL,
while the tissue level reached a concentration of
10.28 ± 2.18 ng/mg (n = 3; data not shown). Alteration in
liver or kidney function during the treatment period was
not observed since liver enzymes [alanine transaminase
(ALT), aspartate transaminase (AST)] as well as serum
creatinine were similar in treated and control mice (n = 7;
P = NS; Table 1).
Mean occlusion time due to thrombus formation equaled
27.9 ± 4.2 min in control mice as compared to
50.9 ± 8.9 min in dronedarone-treated mice (n = 7;
P \ 0.05; Fig. 1a). Real-time blood flow measurement
demonstrated that the two curves separated after 15 min
(Fig. 1b). In contrast, initial blood flow in the carotid artery
and heart rate did not differ between vehicle- and drone-
darone-treated animals (n = 7; P = NS; Table 2).
Dronedarone reduces platelet aggregation,
but not platelet turnover
Maximal platelet aggregation induced by thrombin or
collagen was impaired in dronedarone-treated animals as
compared to controls (n = 11; P \ 0.05; Fig. 2a, c). Time
to begin of aggregation (lag time) in response to thrombin
or collagen tended to be prolonged after dronedarone
treatment (n = 11; P = 0.08; Fig. 2b, d). In contrast, ADP
and botrocetin-induced platelet aggregation was not altered
by dronedarone as compared to controls (n = 4–11;
P = NS; Table 3).
Total platelet number (n = 7; P = NS; Fig. 3a) as well
as platelet turnover remained unaffected by dronedarone.
Turnover was analyzed by measuring the RNA content of
platelets as a marker for immature platelets, and platelet
degradation was assessed by determining the glycocalicin
index. Neither the level of immature platelets (n = 5;
P = NS; Fig. 3b) nor platelet degradation (n = 6;
Table 1 Liver and kidney function were not affected by dronedarone
treatment
Control (n = 7) Dronedarone (n = 7)
AST (U/L) 89.1 ± 15.2 78.9 ± 6.9
ALT (U/L) 23.2 ± 1.8 28.9 ± 1.3
Creatinine (lmol/L) 18.9 ± 1.3 19.5 ± 1.1
AST alanine transaminase, ALT aspartate transaminase
Basic Res Cardiol (2012) 107:302 Page 3 of 8
123
P = NS; Fig. 3c) was altered in the presence of
dronedarone.
Expression of plasminogen activator inhibitor-1 (PAI1),
but not tissue factor (TF) or TF pathway inhibitor
(TFPI), is reduced by dronedarone treatment
Dronedarone significantly reduced PAI1 expression, an
important anti-fibrinolytic factor, both at the mRNA and
the protein level (n = 6–8; P \ 0.05; Fig. 4a, b). In con-
trast, expression of tPA, a pro-fibrinolytic parameter,
remained unchanged (n = 6–7; P = NS; Fig. 4c). Simi-
larly, the level of TF mRNA, the key trigger of the coag-
ulation cascade, as well as its physiological inhibitor, TF
pathway inhibitor (TFPI), were not altered by dronedarone
treatment (n = 7; P = NS; Table 4).
Dronedarone does not alter coagulation times
Prothrombin time (PT) and activated partial thromboplastin
time (aPTT) remained unaffected by dronedarone treat-
ment (n = 7–10; P = NS; Table 4).
Discussion
This study demonstrates that dronedarone impairs throm-
bus formation at plasma concentrations similar to those
observed in humans. These data reveal a novel pleiotropic
action of dronedarone, which offers an explanation for the
previously observed beneficial clinical effects of this sub-
stance. The effect on thrombosis was paralleled by an
inhibition of platelet aggregation as well as PAI1 expres-
sion, whereas no direct effect of dronedarone on the
expression of coagulation factors including TF was
observed. Hence, the antithrombotic effect of dronedarone
described herein is most probably due to an inhibition of
both platelet aggregation and activation of fibrinolysis.
Patients receiving the usual dronedarone treatment
(400 mg orally twice a day) exhibit peak steady state
plasma concentrations between 85 and 150 ng/mL [7].
Hence, even though the dronedarone doses applied in our
study are higher as compared to humans, the dronedarone
plasma concentrations measured are within the range
reached in patients. Thus, the observed anti-thrombotic
effect of dronedarone occurs under clinically relevant
conditions. Furthermore, in this animal study, there were
no signs of early dronedarone toxicity since liver enzymes
and creatinine level were not changed.
ACS is caused by thrombus formation, which results
from an imbalance between procoagulant factors, platelet
activation and fibrinolysis [18]. Most commonly, a coro-
nary is formed on top of a ruptured atherosclerotic plaque
[23], which leads to the exposure of highly procoagulant
plaque material activating the coagulation system and
platelets [2, 22]. Both TF and platelets are thereby crucially
involved since TF is the key activator of the coagulation
cascade [1], and inhibition of platelets represents the main
goal in acute coronary syndromes. On the other hand, PAI1
and tPA regulate the fibrinolytic system and may promote
thrombus degradation [9, 15]. The anti-thrombotic effect of
dronedarone was paralleled by a reduced platelet activation
Table 2 Hemodynamic parameters were not altered by dronedarone
Control (n = 7–10) Dronedarone (n = 7–10)
Initial blood flow
(mL/min)
0.47 ± 0.048 0.47 ± 0.025
Heart rate (bpm) 320 ± 48 310 ± 81
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Fig. 1 Dronedarone inhibits arterial thrombus formation. a Time to
thrombotic occlusion after mouse carotid artery photochemical injury
in vivo. Dronedarone delayed thrombus formation (*P \ 0.05 vs.
control). b Blood flow recordings of control and dronedarone-treated
mouse during photochemical injury in vivo. Laser injury was initiated
at time point 0 min
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as well as by a diminished PAI1 expression; hence, dron-
edarone impairs thrombus formation by a dual action on
two critical events involved in arterial thrombus formation.
Indeed, the importance of platelets in arterial thrombus
formation is well known, and inhibition of platelet aggre-
gation represents the main target in the medical treatment
of ACS. Moreover, a role for PAI1 in the regulation of
arterial thrombus formation has been described in vivo [9,
15]; and higher PAI1 levels have been detected in the
atherosclerotic plaque from patients with coronary artery
disease [21]. Nevertheless, the present data reveal an
association between PAI1 and thrombus formation, and the
relative contribution of PAI1 reduction versus platelet
inhibition to the antithrombotic effect remains speculative.
Even though a vasodilatory effect of dronedarone has been
described in pigs [11], an alteration in hemodynamic
parameters having the potential to influence the results of
the thrombosis model can be excluded because initial blood
flow and heart rate did not differ between the control and
dronedarone groups.
Dronedarone impaired platelet aggregation due to
stimulation with thrombin and collagen, whereas it did not
aggregate in response to ADP and botrocetin. The cellular
effects of thrombin and ADP receptors—similar to other
G-protein coupled receptors—are mediated by cAMP.
Dronedarone’s pattern of action therefore suggests that it
interferes with platelet aggregation at the receptor level.
Such an effect has been observed for other mediators as
well. The most relevant example is given by clopidogrel, a
potent ADP-receptor inhibitor, selectively interfering with
ADP-induced platelet aggregation [26]. Similarly, biva-
lirudin inhibits platelet aggregation in response to thrombin
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Fig. 2 Dronedarone inhibits platelet aggregation. a–d Dronedarone reduced platelet aggregation in thrombin- and collagen-induced activation
(*P \ 0.05), whereas lag time did not differ between the two groups (P = 0.08)
Table 3 ADP and botrocetin-induced platelet aggregation was not
altered by dronedarone
Control
(n = 4–9)
Dronedarone
(n = 7–10)
ADP, max. aggregation (X) 3.4 ± 0.9 3.3 ± 0.96
ADP, lag time (s) 249 ± 65 321 ± 101
Botrocetin, max. aggregation (X) 6.8 ± 0.8 9.8 ± 1.1
Botrocetin, lag time (s) 141 ± 25 116 ± 16
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and collagen without affecting other agonists [16]. Hence,
like other drugs, dronedarone inhibits platelet aggregation
by interfering with activation of specific receptors.
An overview about the potential antiarrhythmic effects
of dronedarone was recently published [6]. Dronedarone
has been shown to reduce time to first recurrence in
patients with paroxysmal atrial fibrillation as well as the
rate of first admission for cardiovascular events or death
from any cause [14]. Trials investigating the role of
dronedarone in heart failure patients failed to confirm these
results in this patient group [17]. In additional to these
antiarrhythmic effects, dronedarone exerts various pleio-
tropic actions. Mice pretreated with dronedarone exhibited
a reduced myocardial infarction in a ligation ischemia
model, probably due to attenuation of calcium overload
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Fig. 3 Dronedarone does not change platelet turnover. a Total
platelet number did not differ between the two groups (P = NS).
b Dronedarone did not change the number of immature platelets
(P = NS). c Glycocalicin index was not altered after dronedarone
treatment (P = NS)
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a, b PAI1 mRNA and protein expression in the arterial wall.
Dronedarone reduced PAI1 expression (*P \ 0.05). c tPA expression
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Page 6 of 8 Basic Res Cardiol (2012) 107:302
123
during ischemia [13, 20]. Similarly, dronedarone pretreat-
ment reduced the area of cerebral infarction in rats [8, 13],
and the expression of ischemia-related genes after rapid
atrial pacing was impaired in pigs treated with the drug
resulting in prevention of ventricular microcirculatory
abnormalities [3]. Hence, besides the pleiotropic anti-
thrombotic effect described in this study, other beneficial
effects of this kind have been observed for dronedarone.
In the ATHENA trial (A Placebo-Controlled, Double-
Blind, Parallel Arm Trial to Assess the Efficacy of Dron-
edarone 400 mg bid for the Prevention of Cardiovascular
Hospitalisation or Death from Any Cause in patients with
Atrial Fibrillation), 4,628 patients were randomized to
either dronedarone (400 mg bid) or placebo [14]. In these
patients suffering from atrial fibrillation, dronedarone
reduced the combined endpoint of hospitalisation for car-
diovascular causes and cardiovascular death, which was
driven primarily by the reduction in cardiovascular hospi-
talisations. Furthermore, first hospitalisations for acute
coronary syndromes (62 in the dronedarone group vs. 89 in
the placebo group, P = 0.02) were significantly lower in
the dronedarone group. While the reduced number of first
hospitalisations due to atrial fibrillation is likely caused by
the anti-arrhythmic effect of dronedarone, the reason for
the decrease in hospitalisations for acute coronary syn-
dromes is not that obvious. A lower heart rate and thereby
anti-ischemic effect may play a role, but an additional
pleiotropic anti-thrombotic effect, as described in the
present study, cannot be ruled out. In contrast, the
PALLAS trial (Permanent Atrial Fibrillation Outcome
Study Using Dronedarone on Top of Standard Therapy) [5]
demonstrated a higher rate of adverse cardiovascular
events. The reason for the opposite outcome between
ATHENA and PALLAS has widely been discussed, but
remains unknown, in particular since direct comparison of
the two studies is difficult. Patients in PALLAS were older,
had a higher prevalence of congestive heart failure, and
were more frequently on digoxin. The higher number of
cardiovascular risk factors in patients of the PALLAS study
and particularly the greater prevalence of congestive heart
failure may be important factors contributing to the
negative outcome of that study. Here, we provide evidence
that dronedarone at clinically relevant concentrations
inhibits arterial thrombus formation in a mouse model. The
reduced number of first hospitalisations due to acute cor-
onary syndromes in the ATHENA trial could well be
explained by the pleiotropic anti-thrombotic effect descri-
bed herein. Even though general survival was worse in
dronedarone-treated patients and more cardiovascular
events occurred in the PALLAS study, the number of
myocardial infarctions did not differ. It may be possible
that inhibition of arterial thrombus formation by droneda-
rone was equally active in the patients from PALLAS, but
this beneficial effect was counterbalanced by the increase
in other adverse events. To what extent dronedarone
influences thrombus formation in a low-shear stress envi-
ronment (e.g. venous system, left and right atrium) cannot
be answered by this analysis since the pathophysiological
mechanisms between arterial and venous thrombus for-
mation are markedly different.
In summary, the present study demonstrates that dron-
edarone, at plasma concentrations similar to those occur-
ring in humans, delays arterial thrombosis in vivo most
probably through inhibition of platelet aggregation and
enhancement of fibrinolysis. These findings thus offer
novel insights into the possible reduction in ACS observed
with dronedarone.
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